Â鶹¸ßÇå

POSITIONS:

Attending Physician, Division of Hematology and Medical Oncology, Weill Cornell, New York and New York Presbyterian Hospital Brooklyn, New York

PROFESSIONAL TRAINING:

Residency, Internal Medicine, Albert Einstein College of Medicine, Bronx, New York, 1996-99

Fellowship, Hematology Oncology, Montefiore Hospital, New York, New York, 1999-2002

Dr. Paul is an expert in the treatment of head and neck and lung cancer with a track record of developing successful multidisciplinary approaches to treat these conditions. He has also made major contributions as a translational and clinical researcher. Demonstrating a national and international presence in his field, he has widely presented his research defining specific therapeutic targets or processes that can be targeted for the improved treatment of cancer patients.

Dr. Paul received his MD from the Carol Davila Faculty of Medicine in Bucharest, Romania in 1993. At the Faculty of Paris 7, in 1995 he received his Clinical Oncology Diploma and in 1996 he received his Chronobiology Diploma and a Masters Degree in the Biology of Aging from the Faculty of Paris 6. In 2016, Dr. Paul received a PhD summa cum laude in Personalized Clinical Oncology, from the Faculty of Medicine in Craiova, Romania. Following his internal medicine residency at the Jacobi Hospital in the Bronx, he completed a hematology and medical oncology fellowship at Montefiore Hospital in 2002. He was a junior faculty member at Weill Cornell Medical College from 2003-2012 when he served as an Attending Physician in Hematology-Oncology at Lincoln Medical and Mental Health Center. Since 2012, he has been an Assistant Professor of Medicine at the Northwell Hofstra School of Medicine and an Attending Physician at the Northwell Health Monter Cancer Center. He has also been an Assistant Professor at the Feinstein Institute for Medical Research since 2017.

Dr. Paul has a strong background as a translational and clinical researcher. Since 2003, he has been Principal Investigator or Local Principal Investigator on 27 studies, and co-Principal Investigator on 5 others. He has designed and conducted several investigator-initiated studies and initiated 2 FDA approved investigational new drug studies. The results of Dr. Paul’s research have been significant. He designed the first in-man pilot study that uses [18F] Fluorodeoxyglucose (FDG) for the targeted treatment of cancer, obtaining approval from the FDA and funding from the Northwell Health Cancer Institute.